Financhill
Sell
28

BIOLQ Quote, Financials, Valuation and Earnings

Last price:
$0.0100
Seasonality move :
-2.06%
Day range:
$0.0109 - $0.0130
52-week range:
$0.0040 - $0.2000
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.01x
P/B ratio:
--
Volume:
9.5K
Avg. volume:
64K
1-year change:
-91.23%
Market cap:
$475.8K
Revenue:
$49.2M
EPS (TTM):
-$2.04

BIOLQ Analysts' Consensus Rating

The 2 analysts providing 12-month price projections for Biolase shares anticipate an average target of $1.2000, ranging from a low estimate of $0.4000 to a high estimate of $2.0000. This average target implies a growth of 15284.62% compared to the current stock price of $0.0130.

Consensus Price Target

$1.2000

Highest Price Target

$2.0000

Lowest Price Target

$0.4000

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Analyst Ratings

6M Ago 1M Ago Current
Buy 1 0 1

Hold 0 0 1

Sell 0 0 0
Consensus Buy -- Leans Bullish

BIOLQ Recommendation Trends

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is QuantumScape a Buy Now?
Is QuantumScape a Buy Now?

QuantumScape (NYSE:QS) is an innovative EV battery company that specializes…

Is Vertex Stock Still a Good Buy?
Is Vertex Stock Still a Good Buy?

Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…

Is Okta Stock Finally Gaining Investor Confidence?
Is Okta Stock Finally Gaining Investor Confidence?

Given how digital transformation has proliferated, cyberattacks have also been…

Stock Ideas

Buy
61
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
58
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 37x

Alerts

Sell
50
RGC alert for May 1

Regencell Bioscience Holdings [RGC] is up 20.58% over the past day.

Sell
38
WGS alert for May 1

GeneDx Holdings [WGS] is down 6.85% over the past day.

Sell
43
VICR alert for May 1

Vicor [VICR] is down 1.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock